Viatris is a global pharmaceutical company formed in 2020 through the merger of Mylan and Upjohn, a legacy division of Pfizer. With a portfolio encompassing brand-name, generic, and over-the-counter medicines, its mission is to empower people worldwide to live healthier at every stage of life. The company operates at a massive scale, with a presence in over 165 countries, a vast manufacturing network, and a complex supply chain designed to deliver high-quality medicines efficiently and reliably.

Why AI matters at this scale

For a corporation of Viatris's size and sector, AI is not a speculative technology but a critical lever for competitive advantage and operational resilience. The pharmaceutical industry faces immense pressure from pricing, complex regulations, and lengthy R&D cycles. At a 10,000+ employee scale, even marginal efficiency gains in manufacturing yield, supply chain logistics, or clinical trial design translate into hundreds of millions in savings and accelerated patient access. AI provides the analytical horsepower to optimize these colossal, data-rich processes, turning operational data into a strategic asset. For a post-merger entity like Viatris, AI also offers a path to harmonize disparate legacy systems and create a unified, intelligent operational backbone.

Concrete AI opportunities with ROI

1. Supply Chain & Inventory Intelligence: Viatris's global distribution of essential medicines is a prime target for AI. Machine learning models can analyze historical sales, seasonal illness trends, and local economic data to predict demand with high accuracy. This enables dynamic inventory management, reducing costly overstock and preventing critical shortages. The ROI is direct: lower carrying costs, reduced waste, and improved service levels that solidify customer trust and contractual performance.

2. Accelerated Generic & Biosimilar R&D: Developing complex generics and biosimilars is a resource-intensive race. AI can dramatically shorten the early development phase. Generative AI models can propose viable molecular structures or formulations, while ML can analyze past clinical trial data to design more efficient, smaller studies for proving bioequivalence. The ROI is in time-to-market: bringing a product to market months earlier in a competitive landscape can capture significant market share and revenue.

3. Predictive Maintenance in Manufacturing: The company's extensive manufacturing footprint involves high-value, continuous-operation equipment. Implementing AI-driven predictive maintenance by analyzing sensor data from machinery can forecast failures before they happen. This minimizes unplanned downtime, ensures consistent production quality (critical for GMP compliance), and extends asset life. The ROI is clear through increased Overall Equipment Effectiveness (OEE), lower emergency repair costs, and higher throughput.

Deployment risks specific to this size band

Deploying AI at the enterprise scale of Viatris introduces unique challenges beyond technological proof-of-concept. Integration Complexity is paramount, as AI systems must connect with a patchwork of legacy ERP (e.g., SAP), CRM, and manufacturing systems from merged entities, requiring robust data pipelines and middleware. Regulatory & Compliance Hurdles are steep in pharma; any AI impacting drug development (GxP) or manufacturing (GMP) must be rigorously validated, auditable, and explainable to meet FDA and global health authority standards. Change Management at Scale is critical; rolling out AI tools to tens of thousands of employees across diverse global cultures requires extensive training and a clear narrative on how AI augments rather than replaces roles, to secure buy-in and realize adoption benefits.